These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19475539)

  • 21. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.
    Wong SL; Cao G; Mack R; Granneman GR
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):146-51. PubMed ID: 9562230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
    Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sertindole, a potent antagonist at dopamine D₂ receptors, induces autophagy by increasing reactive oxygen species in SH-SY5Y neuroblastoma cells.
    Shin JH; Park SJ; Kim ES; Jo YK; Hong J; Cho DH
    Biol Pharm Bull; 2012; 35(7):1069-75. PubMed ID: 22791154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.
    Feng MR; Corbin AE; Wang Y; Christoffersen CL; Wiley JN; Strenkoski CA; Tucker EV; Ninteman FW; Meltzer LT; Heffner TG; Wright DS
    Pharm Res; 1997 Mar; 14(3):329-36. PubMed ID: 9098876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain.
    Takahashi Y; Kusumi I; Ishikane T; Koyama T
    J Neural Transm (Vienna); 1998; 105(2-3):181-91. PubMed ID: 9660096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [THE EFFECTS OF D(1)- AND D(2)-TYPE DOPAMINERGIC RECEPTOR ANTAGONISTS ON LEARNING PERFORMANCE IN ANDROGEN DEFICIENT RATS.].
    Fedotoval YO
    Eksp Klin Farmakol; 2017; 80(1):3-8. PubMed ID: 29873995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment.
    Skarsfeldt T
    Synapse; 1992 Jan; 10(1):25-33. PubMed ID: 1346943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.
    Lehr T; Staab A; Tillmann C; Nielsen EØ; Trommeshauser D; Schaefer HG; Kloft C
    Br J Pharmacol; 2008 Jan; 153(1):164-74. PubMed ID: 17982477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma.
    Canal-Raffin M; Déridet E; Titier K; Frakra E; Molimard M; Moore N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jan; 814(1):61-7. PubMed ID: 15607708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
    Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
    Eur J Pharmacol; 2016 Oct; 789():202-214. PubMed ID: 27395799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation between cortical dopamine D(2) receptor occupancy and suppression of conditioned avoidance response in non-human primate.
    Takano A; Suhara T; Maeda J; Ando K; Okauchi T; Obayashi S; Nakayama T; Kapur S
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):330-2. PubMed ID: 15149302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats.
    Iorio LC; Cohen M; Coffin VL
    J Pharmacol Exp Ther; 1991 Jul; 258(1):118-23. PubMed ID: 1830098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
    Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
    J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.